{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:01:17Z","timestamp":1788843677610,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114705"],"award-info":[{"award-number":["70114705"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"EC | ERC | HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["834974"],"award-info":[{"award-number":["834974"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031B0843D"],"award-info":[{"award-number":["031B0843D"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["Plan Cancer 2014-2019"],"award-info":[{"award-number":["Plan Cancer 2014-2019"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Circulating tumor DNA (ctDNA) is the cornerstone of liquid biopsy diagnostics, revealing clinically relevant genomic aberrations from blood of cancer patients. Genomic analysis of single circulating tumor cells (CTCs) could provide additional insights into intra-patient heterogeneity, but it requires whole-genome amplification (WGA) of DNA, which might introduce bias. Here, we describe a novel approach based on mass spectrometry for mutation detection from individual CTCs not requiring WGA and complex bioinformatics pipelines. After establishment of our protocol on tumor cell line-derived single cells, it was validated on CTCs of 33 metastatic melanoma patients and the mutations were compared to those obtained from tumor tissue and ctDNA. Although concordance with tumor tissue was superior for ctDNA over CTC analysis, a larger number of mutations were found within CTCs compared to ctDNA (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039), including mutations in melanoma driver genes, or those associated with resistance to therapy or metastasis. Thus, our results demonstrate proof-of-principle data that CTC analysis can provide clinically relevant genomic information that is not redundant to tumor tissue or ctDNA analysis.\n                  <\/jats:p>","DOI":"10.1038\/s44321-024-00082-6","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T09:02:19Z","timestamp":1718787739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8591-2237","authenticated-orcid":false,"given":"Mark","family":"Sementsov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6308-0242","authenticated-orcid":false,"given":"Leonie","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-3909","authenticated-orcid":false,"given":"Julian","family":"K\u00f6tt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7741-7555","authenticated-orcid":false,"given":"Alexander","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Lusque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-8281","authenticated-orcid":false,"given":"Sarah","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3492-3780","authenticated-orcid":false,"given":"Bertille","family":"Segier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-8650","authenticated-orcid":false,"given":"Beate","family":"Volkmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Greinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia-Christina","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-6708","authenticated-orcid":false,"given":"Darryl","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2794-0003","authenticated-orcid":false,"given":"Benjamin","family":"Deitert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Thewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-3466","authenticated-orcid":false,"given":"Andreas","family":"Trumpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Belloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Peine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-0888","authenticated-orcid":false,"given":"Harriett","family":"Wikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-5643","authenticated-orcid":false,"given":"Sabine","family":"Riethdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-7137","authenticated-orcid":false,"given":"Stefan W","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-2772","authenticated-orcid":false,"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1786-9760","authenticated-orcid":false,"given":"Laura","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"82_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R et al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446\u2013451","journal-title":"Nature"},{"key":"82_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL et al (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 616:553\u2013562","journal-title":"Nature"},{"key":"82_CR3","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res C, Pantel K (2021) Liquid biopsy: from discovery to clinical application. Cancer Discov 11:858\u2013873","journal-title":"Cancer Discov"},{"key":"82_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29416-z","volume":"13","author":"D-B Asante","year":"2023","unstructured":"Asante D-B, Mohan GRKA, Acheampong E, Ziman M, Calapre L, Meniawy TM, Gray ES, Beasley AB (2023) Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients. Sci Rep 13:2552","journal-title":"Sci Rep"},{"key":"82_CR5","doi-asserted-by":"publisher","first-page":"56066","DOI":"10.18632\/oncotarget.10701","volume":"8","author":"A Babayan","year":"2016","unstructured":"Babayan A, Alawi M, Gormley M, M\u00fcller V, Wikman H, McMullin RP, Smirnov DA, Li W, Geffken M, Pantel K et al (2016) Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget 8:56066\u201356080","journal-title":"Oncotarget"},{"key":"82_CR6","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.3390\/cells9112337","volume":"9","author":"Y Belloum","year":"2020","unstructured":"Belloum Y, Janning M, Mohme M, Simon R, Kropidlowski J, Sartori A, Irwin D, Westphal M, Lamszus K, Loges S et al (2020) Discovery of targetable genetic alterations in NSCLC patients with different metastatic patterns using a MassARRAY-based circulating tumor DNA assay. Cells 9:2337","journal-title":"Cells"},{"key":"82_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/PO.19.00174","volume":"4","author":"J Braune","year":"2020","unstructured":"Braune J, Keller L, Schiller F, Graf E, Rafei-Shamsabadi D, Wehrle J, Follo M, Philipp U, Hussung S, Pfeifer D et al (2020) Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma. JCO Precis Oncol 4:20\u201331","journal-title":"JCO Precis Oncol"},{"key":"82_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/1878-0261.12391","volume":"13","author":"L Calapre","year":"2019","unstructured":"Calapre L, Giardina T, Robinson C, Reid AL, Al\u2010Ogaili Z, Pereira MR, McEvoy AC, Warburton L, Hayward NK, Khattak MA et al (2019) Locus\u2010specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Mol Oncol 13:171\u2013184","journal-title":"Mol Oncol"},{"key":"82_CR9","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/1878-0261.13150","volume":"16","author":"AK Cani","year":"2022","unstructured":"Cani AK, Dolce EM, Darga EP, Hu K, Liu C-J, Pierce J, Bradbury K, Kilgour E, Aung K, Schiavon G et al (2022) Serial monitoring of genomic alterations in circulating tumor cells of ER-positive\/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. Mol Oncol 16:1969\u20131985","journal-title":"Mol Oncol"},{"key":"82_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nm.4239","volume":"23","author":"L Carter","year":"2017","unstructured":"Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, Li Y, Burt DJ, Antonello J, Morrow CJ et al (2017) Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med 23:114\u2013119","journal-title":"Nat Med"},{"key":"82_CR11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.jid.2020.01.027","volume":"140","author":"GA Chang","year":"2020","unstructured":"Chang GA, Wiggins JM, Corless BC, Syeda MM, Tadepalli JS, Blake S, Fleming N, Darvishian F, Pavlick A, Berman R et al (2020) TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors. J Invest Dermatol 140:1609\u20131618.e7","journal-title":"J Invest Dermatol"},{"key":"82_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ccr.2011.10.030","volume":"20","author":"WE Damsky","year":"2011","unstructured":"Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M et al (2011) \u03b2-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20:741\u2013754","journal-title":"Cancer Cell"},{"key":"82_CR13","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3390\/cancers12082228","volume":"12","author":"RJ Diefenbach","year":"2020","unstructured":"Diefenbach RJ, Lee JH, Menzies AM, Carlino MS, Long GV, Saw RPM, Howle JR, Spillane AJ, Scolyer RA, Kefford RF et al (2020) Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. Cancers 12:2228","journal-title":"Cancers"},{"key":"82_CR14","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/s41416-022-01962-9","volume":"127","author":"D Fernandez-Garcia","year":"2022","unstructured":"Fernandez-Garcia D, Nteliopoulos G, Hastings RK, Rushton A, Page K, Allsopp RC, Ambasager B, Gleason K, Guttery DS, Ali S et al (2022) Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer. Br J Cancer 127:1858\u20131864","journal-title":"Br J Cancer"},{"key":"82_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/2159-8290.CD-19-0356","volume":"9","author":"Y Gao","year":"2019","unstructured":"Gao Y, Maria A, Na N, da Cruz Paula A, Gorelick AN, Hechtman JF, Carson J, Lefkowitz RA, Weigelt B, Taylor BS et al (2019) V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer. Cancer Discov 9:1182\u20131191","journal-title":"Cancer Discov"},{"key":"82_CR16","doi-asserted-by":"publisher","first-page":"E1685","DOI":"10.3390\/cancers11111685","volume":"11","author":"K Gorges","year":"2019","unstructured":"Gorges K, Wiltfang L, Gorges TM, Sartori A, Hildebrandt L, Keller L, Volkmer B, Peine S, Babayan A, Moll I et al (2019) Intra-patient heterogeneity of circulating tumor cells and circulating tumor DNA in blood of melanoma patients. Cancers 11:E1685","journal-title":"Cancers"},{"key":"82_CR17","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/jid.2015.127","volume":"135","author":"ES Gray","year":"2015","unstructured":"Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M (2015) Circulating melanoma cell subpopulations: their heterogeneity and differential responses to treatment. J Invest Dermatol 135:2040\u20132048","journal-title":"J Invest Dermatol"},{"key":"82_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jmoldx.2018.12.001","volume":"21","author":"ES Gray","year":"2019","unstructured":"Gray ES, Witkowski T, Pereira M, Calapre L, Herron K, Irwin D, Chapman B, Khattak MA, Raleigh J, Hatzimihalis A et al (2019) Genomic analysis of circulating tumor DNA using a melanoma-specific UltraSEEK oncogene panel. J Mol Diagn 21:418\u2013426","journal-title":"J Mol Diagn"},{"key":"82_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10555-022-10075-x","volume":"42","author":"I Heidrich","year":"2023","unstructured":"Heidrich I, Deitert B, Werner S, Pantel K (2023) Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. Cancer Metastasis Rev 42:161\u2013182","journal-title":"Cancer Metastasis Rev"},{"key":"82_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20:71\u201388","journal-title":"Nat Rev Genet"},{"key":"82_CR21","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1002\/ijc.30007","volume":"138","author":"GE Hvichia","year":"2016","unstructured":"Hvichia GE, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, M\u00fcller V, Loges S, Neves RPL, Stoecklein NH et al (2016) A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer 138:2894\u20132904","journal-title":"Int J Cancer"},{"key":"82_CR22","doi-asserted-by":"publisher","first-page":"e0141579","DOI":"10.1371\/journal.pone.0141579","volume":"10","author":"SM Hykin","year":"2015","unstructured":"Hykin SM, Bi K, McGuire JA (2015) Fixing formalin: a method to recover genomic-scale DNA sequence data from formalin-fixed museum specimens using high-throughput sequencing. PLoS ONE 10:e0141579","journal-title":"PLoS ONE"},{"key":"82_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08908-z","volume":"22","author":"GS Karachaliou","year":"2022","unstructured":"Karachaliou GS, Alkallas R, Carroll SB, Caressi C, Zakria D, Patel NM, Trembath DG, Ezzell JA, Pegna GJ, Googe PB et al (2022) The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. BMC Cancer 22:38","journal-title":"BMC Cancer"},{"key":"82_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","volume":"124","author":"L Keller","year":"2021","unstructured":"Keller L, Belloum Y, Wikman H, Pantel K (2021) Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer 124:345\u2013358","journal-title":"Br J Cancer"},{"key":"82_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","volume":"19","author":"L Keller","year":"2019","unstructured":"Keller L, Pantel K (2019) Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer 19:553\u2013567","journal-title":"Nat Rev Cancer"},{"key":"82_CR26","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/jid.2012.468","volume":"133","author":"L Khoja","year":"2012","unstructured":"Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, Califano R, Clack G, Hughes A, Dive C (2012) Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol 133:1582\u20131590","journal-title":"J Invest Dermatol"},{"key":"82_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/cancers12020442","volume":"12","author":"C Koch","year":"2020","unstructured":"Koch C, Joosse SA, Schneegans S, Wilken OJW, Janning M, Loreth D, M\u00fcller V, Prieske K, Banys-Paluchowski M, Horst LJ et al (2020) Pre-analytical and analytical variables of label-independent enrichment and automated detection of circulating tumor cells in cancer patients. Cancers 12:442","journal-title":"Cancers"},{"key":"82_CR28","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.3390\/cancers12103002","volume":"12","author":"P-J Lamy","year":"2020","unstructured":"Lamy P-J, van der Leest P, Lozano N, Becht C, Duboeuf F, Groen HJM, Hilgers W, Pourel N, Rifaela N, Schuuring E et al (2020) Mass spectrometry as a highly sensitive method for specific circulating tumor DNA analysis in NSCLC: a comparison study. Cancers 12:3002","journal-title":"Cancers"},{"key":"82_CR29","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1038\/s41388-021-01928-w","volume":"40","author":"S Liebs","year":"2021","unstructured":"Liebs S, Eder T, Klauschen F, Sch\u00fctte M, Yaspo M-L, Keilholz U, Tinhofer I, Kidess-Sigal E, Braunholz D (2021) Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities. Oncogene 40:5204\u20135212","journal-title":"Oncogene"},{"key":"82_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1373\/clinchem.2019.307140","volume":"66","author":"SY Lin","year":"2020","unstructured":"Lin SY, Chang S-C, Lam S, Irene Ramos R, Tran K, Ohe S, Salomon MP, Bhagat AAS, Teck Lim C, Fischer TD et al (2020) Prospective molecular profiling of circulating tumor cells from patients with melanoma receiving combinatorial immunotherapy. Clin Chem 66:169\u2013177","journal-title":"Clin Chem"},{"key":"82_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nbt.2892","volume":"32","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang C-Z, Shalek AK, Satija R et al (2014) Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 32:479\u2013484","journal-title":"Nat Biotechnol"},{"key":"82_CR32","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-19-2670","volume":"26","author":"A Lucci","year":"2020","unstructured":"Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC et al (2020) Circulating tumor cells and early relapse in node-positive melanoma. Clin Cancer Res 26:1886\u20131895","journal-title":"Clin Cancer Res"},{"key":"82_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2017.03.012","volume":"78","author":"D Massi","year":"2017","unstructured":"Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G et al (2017) Baseline \u03b2-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. Eur J Cancer 78:70\u201381","journal-title":"Eur J Cancer"},{"key":"82_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y et al (2020) Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11:5327","journal-title":"Nat Commun"},{"key":"82_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jmoldx.2015.08.001","volume":"18","author":"MJ Mosko","year":"2016","unstructured":"Mosko MJ, Nakorchevsky AA, Flores E, Metzler H, Ehrich M, van den Boom DJ, Sherwood JL, Nygren AOH (2016) Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry. J Mol Diagn 18:23\u201331","journal-title":"J Mol Diagn"},{"key":"82_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9760","volume":"6","author":"M Murtaza","year":"2015","unstructured":"Murtaza M, Dawson S-J, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin S-F, Tsui DWY, Marass F, Gale D et al (2015) Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 6:8760","journal-title":"Nat Commun"},{"key":"82_CR37","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","volume":"24","author":"JI Odegaard","year":"2018","unstructured":"Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, Fairclough SR, Zill OA, Sikora M, Mokhtari R et al (2018) Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin Cancer Res 24:3539\u20133549","journal-title":"Clin Cancer Res"},{"key":"82_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00203-1","volume":"5","author":"M Oulhen","year":"2021","unstructured":"Oulhen M, Pawlikowska P, Tayoun T, Garonzi M, Buson G, Forcato C, Manaresi N, Aberlenc A, Mezquita L, Lecluse Y et al (2021) Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. NPJ Precis Oncol 5:67","journal-title":"NPJ Precis Oncol"},{"key":"82_CR39","doi-asserted-by":"publisher","first-page":"6671","DOI":"10.1158\/1078-0432.CCR-19-1176","volume":"25","author":"E Pailler","year":"2019","unstructured":"Pailler E, Faugeroux V, Oulhen M, Mezquita L, Laporte M, Honor\u00e9 A, Lecluse Y, Queffelec P, NgoCamus M, Nicotra C et al (2019) Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer. Clin Cancer Res 25:6671\u20136682","journal-title":"Clin Cancer Res"},{"key":"82_CR40","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1158\/0008-5472.CAN-17-2686","volume":"78","author":"C Paoletti","year":"2018","unstructured":"Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu C-J, Chu D et al (2018) Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Res 78:1110\u20131122","journal-title":"Cancer Res"},{"key":"82_CR41","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","volume":"25","author":"AR Parikh","year":"2019","unstructured":"Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE et al (2019) Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 25:1415\u20131421","journal-title":"Nat Med"},{"key":"82_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23394-4","volume":"12","author":"B Pereira","year":"2021","unstructured":"Pereira B, Chen CT, Goyal L, Walmsley C, Pinto CJ, Baiev I, Allen R, Henderson L, Saha S, Reyes S et al (2021) Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. Nat Commun 12:3199","journal-title":"Nat Commun"},{"key":"82_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6890-4-1","volume":"4","author":"N Quach","year":"2004","unstructured":"Quach N, Goodman MF, Shibata D (2004) In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR. BMC Clin Pathol 4:1","journal-title":"BMC Clin Pathol"},{"key":"82_CR44","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","volume":"13","author":"S Riethdorf","year":"2007","unstructured":"Riethdorf S, Fritsche H, M\u00fcller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, J\u00e4nicke F et al (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13:920\u2013928","journal-title":"Clin Cancer Res"},{"key":"82_CR45","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.3390\/cancers14163925","volume":"14","author":"T Rossi","year":"2022","unstructured":"Rossi T, Angeli D, Tebaldi M, Fici P, Rossi E, Rocca A, Palleschi M, Maltoni R, Martinelli G, Fabbri F et al (2022) Dissecting molecular heterogeneity of circulating tumor cells (CTCs) from metastatic breast cancer patients through copy number aberration (CNA) and single nucleotide variant (SNV) single cell analysis. Cancers 14:3925","journal-title":"Cancers"},{"key":"82_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00445-7","volume":"8","author":"F Roth\u00e9","year":"2022","unstructured":"Roth\u00e9 F, Venet D, Peeters D, Rouas G, Rediti M, Smeets D, Dupont F, Campbell P, Lambrechts D, Dirix L et al (2022) Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. NPJ Breast Cancer 8:79","journal-title":"NPJ Breast Cancer"},{"key":"82_CR47","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/bjc.2012.12","volume":"106","author":"K Sakaizawa","year":"2012","unstructured":"Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H et al (2012) Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106:939\u2013946","journal-title":"Br J Cancer"},{"key":"82_CR48","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P et al (2016) Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res 22:567\u2013574","journal-title":"Clin Cancer Res"},{"key":"82_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523:231\u2013235","journal-title":"Nature"},{"key":"82_CR50","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/cancers12061588","volume":"12","author":"S Weber","year":"2020","unstructured":"Weber S, Spiegl B, Perakis SO, Ulz CM, Abuja PM, Kashofer K, van der Leest P, Azpurua MA, Tamminga M, Brudzewsky D et al (2020) Technical evaluation of commercial mutation analysis platforms and reference materials for liquid biopsy profiling. Cancers 12:1588","journal-title":"Cancers"},{"key":"82_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00009","volume":"1","author":"SQ Wong","year":"2017","unstructured":"Wong SQ, Raleigh JM, Callahan J, Vergara IA, Ftouni S, Hatzimihalis A, Colebatch AJ, Li J, Semple T, Doig K et al (2017) Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma. JCO Precis Oncol 1:1\u201314","journal-title":"JCO Precis Oncol"},{"key":"82_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2020.08.043","volume":"493","author":"J Yu","year":"2020","unstructured":"Yu J, Gemenetzis G, Kinny-K\u00f6ster B, Habib JR, Groot VP, Teinor J, Yin L, Pu N, Hasanain A, van Oosten F et al (2020) Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. Cancer Lett 493:245\u2013253","journal-title":"Cancer Lett"},{"key":"82_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ccell.2018.05.014","volume":"34","author":"H Zeng","year":"2018","unstructured":"Zeng H, Jorapur A, Shain AH, Lang UE, Torres R, Zhang Y, McNeal AS, Botton T, Lin J, Donne M et al (2018) Bi-allelic loss of CDKN2A initiates melanoma invasion via BRN2 activation. Cancer Cell 34:56\u201368.e9","journal-title":"Cancer Cell"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00082-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:22:35Z","timestamp":1785856955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00082-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,15]]}},"alternative-id":["82"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00082-6","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS, LO, JK, AL, BS, IH, JCS, AA, YB, HW, BD, SR, SD, BV, GR, RS, SP, KP, and LK declare no competing interest. AS and DI are employees of Agena Bioscience and hold shares of Mesa Labs. PM declares participation in Data Safety Monitoring Advisory Boards for MSD, Pierre Fabre, GSK, Roche, Bristol Myers Squibb, Novartis, Sanofi, Beiersdorf, Almirall, Hermal, AMGEN, and Sun-Pharma. CG is a member of the advisory board of, and has received honoraria and travel expenses from Almirall, Amgen, Beiersdorf, BioNTech, Bristol-Myers Squibb, Immunocore, Janssen, MSD Sharp & Dohme, Novartis, Pierre-Fabre, Roche, Sanofi Genzyme, SUN Pharma, Sysmex, ouside the submitted work; CG holds shares of Dermagnostix.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"6"}}